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http://dx.doi.org/10.1016/j.stemcr.2016.08.012SUMMARYParkinson’s disease (PD) is characterized by the selective loss of dopamine neurons in the substantia nigra; however, the mechanism of
neurodegeneration in PD remains unclear. A subset of familial PD is linked tomutations in PARK2 and PINK1, which lead to dysfunctional
mitochondria-related proteins Parkin and PINK1, suggesting that pathways implicated in thesemonogenic forms could play amore gen-
eral role in PD.We demonstrate that the identification of disease-related phenotypes in PD-patient-specific induced pluripotent stem cell
(iPSC)-derivedmidbrain dopamine (mDA) neurons depends on the type of differentiation protocol utilized. In a floor-plate-based but not
a neural-rosette-based directed differentiation strategy, iPSC-derived mDA neurons recapitulate PD phenotypes, including pathogenic
protein accumulation, cell-type-specific vulnerability, mitochondrial dysfunction, and abnormal neurotransmitter homeostasis.We pro-
pose that these form a pathogenic loop that contributes to disease. Our study illustrates the promise of iPSC technology for examining PD
pathogenesis and identifying therapeutic targets.INTRODUCTION
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder and is characterized by the se-
lective loss of midbrain dopamine (mDA) neurons in the
substantia nigra (SN). While the majority of PD cases are
sporadic, there has been considerable progress in the iden-
tification of genes related to familial forms of PD. The study
of such rare mutations may illuminate novel strategies to
predict, understand, and potentially treat PD. A number
of PD animal models have been established, but most of
these have failed to faithfully reproduce the human disease
(Dawson et al., 2010). Recent advances in the derivation
and differentiation of human induced pluripotent stem
cells (iPSCs) and human embryonic stem cells (ESCs) pre-
sent new opportunities for disease modeling (Bellin et al.,
2012). The advent of iPSC technology has enabled PD
modeling directly in patient-specific and disease-relevant
human cells such as mDA neurons, the cell type preferen-
tially lost in the disorder. To study mechanisms of mDA
neuron loss in vitro, it is essential to select an optimized
in vitro protocol to obtain the appropriate cell type.664 Stem Cell Reports j Vol. 7 j 664–677 j October 11, 2016 j ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://creativMany previous PD modeling studies in patient-specific
iPSC lines were conducted using early generation differen-
tiation protocols, which resulted in variable dopamine
(DA) neuron populations in both quality and quantity
(Cooper et al., 2012; Devine et al., 2011; Jiang et al.,
2012; Nguyen et al., 2011). Therefore, the iPSC-derived
DA neuron populations in those studies may have been
heterogeneous and possibly distinct from the actual cells
affected in the PD brain. We previously reported a success-
ful protocol for deriving mDA neurons from human ESCs
and iPSCs (Kriks et al., 2011), which facilitates robust in-
duction of more ‘‘authentic’’ midbrain neurons that ex-
press key mDA markers including the transcription factors
FOXA2 and LMX1A.
Patients with recessively inherited PARK2/Parkin (Kitada
et al., 1998) and PTEN-induced putative kinase 1 (PINK1)
(Valente et al., 2004) mutations represent one of several
monogenic forms of PD. Recent studies demonstrated the
involvement of both Parkin and PINK1 in mitochondrial
function (Imaizumi et al., 2012; Narendra et al., 2010; Sei-
bler et al., 2011). In our study, we first used our floor-plate-
based differentiation protocol to derivemDAneurons fromuthor(s).
ecommons.org/licenses/by-nc-nd/4.0/).
patient-specific PINK1 and PARK2/Parkin mutant human
iPSCs. The PD iPSC lines displayed differentiation proper-
ties comparable with those of control human iPSC or ESC
(H9) lines; however, both PINK1 and Parkin patient-
derived mDA neurons showed increased levels of a-synu-
clein expression at the gene and protein levels. The PD
iPSC-derived mDA neurons also exhibited increased sus-
ceptibility tomitochondrial toxins. Furthermore, we found
mitochondrial abnormalities and increased intracellular
DA levels in floor-plate-derived PD iPSC mDA neurons.
On the contrary, DA neurons generated via a neural
rosette/neuroepithelial (Perrier et al., 2004) rather than
via a floor-plate intermediate (Kriks et al., 2011) did not
show a difference in phenotypes including a-synuclein
levels between disease and control lines. Our findings high-
light the importance of the appropriate mDA neuron iden-
tity for in vitro disease modeling and point to a pathogenic
loop that includes mitochondrial dysfunction, increased
vulnerability, and the accumulation of a-synuclein and
dopamine.RESULTS
Characterization of Differentiation Potential of PD
iPSCs
We analyzed two iPSC lines derived from patients with
PARK2/Parkin (V324A) and PINK1 (Q456X) mutations,
lines established and studied in past reports (Cooper
et al., 2012; Mazzulli et al., 2011, 2016; Miller et al.,
2013; Seibler et al., 2011). For this study, we used our
previously published midbrain floor-plate-based mDA
neuron differentiation protocol (Kriks et al., 2011) to
differentiate the Parkin and PINK1 iPSC as well as control
human iPSC and ESC lines. The mDA neuron protocol is
based on neural induction via dual-SMAD inhibition
(Chambers et al., 2009) and the sequential activation of
SHH and WNT signaling (Kriks et al., 2011). Disease and
control lines were differentiated simultaneously to assess
the efficiency of mDA neuron yield (Figure 1). At day 11
of differentiation, all lines demonstrated a high yield
(70%–90%) of midbrain precursor cells co-expressing
FOXA2 and LMX1A, which are critical markers in mDA
neuron development (Figures 1A and 1B). At day 30 cells
began to express tyrosine hydroxylase (TH), the rate-
limiting enzyme in the production of DA, which was
co-expressed with the midbrain-related transcription fac-
tors FOXA2 and NURR1 (Figures 1C and 1D). Upon
further maturation, cells maintained high levels of
FOXA2/NURR1 and continued to express TH (Figures 1E
and 1F). DA neurons from all lines demonstrated co-
expression with MAP2, a marker of post-mitotic neurons
(Figure S1A).Moreover, DA neurons derived from PD or control iPSCs
lines demonstrated comparable yields of FOXA2, NURR1,
and TH, suggesting suitability for in vitro PD modeling.
In contrast, DA neurons derived using the stromal feeder
(MS5)-based differentiation protocol (Perrier et al., 2004),
whereby cells transit through a neural rosette stage rather
than a floor-plate intermediate, yielded significantly lower
levels (20%–50%) of TH+ neurons (Figures 1G and 1H). The
transcription factors FOXA2/NURR1 were expressed in
only a small proportion of the total cell population, and
cells expressing these markers often did not co-express
TH. Electrophysiological recordings of H9, control iPSC,
and PD iPSC-derived (day 80) DA neurons demonstrated
that the floor-plate-based protocol yields cells with slow
oscillatory action potentials at 3–5 Hz, at a resting mem-
brane potential of45 mV (n = 12 cells). This spontaneous
tonic firing activity is another prominent characteristic of
mDAneurons, including those located in the substantia ni-
gra pars compacta (SNpc) (Figures S2A–S2D). These data
confirm that floor-plate-derived but not neural-rosette-
derived TH+ neurons exhibit marker expression and
functional properties characteristic of midbrain-specific
DA neurons.
Mitochondrial Defects in Differentiated Cells from
PD iPSCs
Parkin and PINK1 proteins are thought to play important
roles in mitochondrial homeostasis, based on studies in
which increased expression of those genes confers protec-
tion from stress-induced cell death. Furthermore, loss of
Parkin and PINK1 makes primary cells more susceptible
to stress and death (Deng et al., 2008; Exner et al.,
2007; Poole et al., 2008; Valente et al., 2004). Based on
such results, it is believed that PARK2/Parkin- and
PINK1-related genetic causes of PD likely involve a loss-
of-function phenotype that leads to the clinical presenta-
tion of the disease (Klein and Schlossmacher, 2006;
Lesage and Brice, 2009). To gain a better understanding
of the Parkin- and PINK1-mediated PD phenotype, we
investigated the presence of mitochondrial abnormalities
that have been described in DA neurons of PD patients
and neuronal cultures (Devi et al., 2008; Imaizumi
et al., 2012; Keeney et al., 2006; Pickrell and Youle,
2008). For both Parkin- and PINK1 iPSC-derived midbrain
neuronal populations, electron microscopy at day 75 of
differentiation revealed the presence of abnormal mito-
chondria (Figure 2A). The PD iPSC-derived neuronal pop-
ulations had a greater proportion of enlarged mitochon-
dria (60%–80% of mitochondria), a finding observed in
a much smaller fraction of control iPSC- or ESC-derived
neurons (Figure 2B) Abnormal mitochondria were also
larger (60%–120%) than those in neurons derived from
control iPSC or ESC (H9) lines (Figure 2C). NeuronsStem Cell Reports j Vol. 7 j 664–677 j October 11, 2016 665
A0
20
40
60
80
100
Day 30
0
20
40
60
80
100
FOXA2
NURR1
TH
Day 45
0
20
40
60
80
100 MS5 Day 45
FO
XA
2/
 T
H
FO
XA
2/
 T
H
FO
XA
2/
 T
H
N
U
R
R
1/
 T
H
N
U
R
R
1
/ T
H
N
U
R
R
1/
 T
H
D
ay 30
D
a y 4
M
5
S5 D
ay 45
FO
XA
2/
 L
M
X1
A
Parkin PINK1 Control-iPSC H9
D
ay 11
0
20
40
60
80
100
Parkin PINK1 Control H9
%
 o
f t
ot
al
 c
el
ls
Day 11
FOXA2
LMX1A
Parkin PINK1 Control-iPSC H9
B
C
D
Parkin PINK1 Control H9
%
 o
f t
ot
al
 c
el
ls
Parkin PINK1 Control-iPSC H9
Parkin PINK1 Control-iPSC H9
Parkin PINK1 Control H9
%
 o
f t
ot
al
 c
el
ls
E
F
Parkin PINK1 Control H9
%
 o
f t
ot
al
 c
el
ls
FOXA2
NURR1
TH
FOXA2
NURR1
TH
G
H
Figure 1. Identical Differentiation Potential of PD iPSC and Control Lines
(A, C, E, and G) Immunocytochemical analysis of in-vitro-derived mDA neuron lineages at day 11 (A; midbrain precursor stage), day 30 (C;
early post-mitotic neuronal stage), and day 45 (E and G; mature neuronal stage) of differentiation. FOXA2, LMX1A, NURR1, and TH
expression was assessed in Parkin and PINK1 iPSC lines, control iPSC, and normal ESC (H9) lines. Representative images in (A), (C), and (E)
illustrate mDA neuron cultures differentiated by the floor-plate-based protocol. Images in (G) illustrate cells differentiated via the
MS5-based protocol. Scale bars, 50 mm.
(B, D, F, and H) Quantification of the data are presented in (A), (C), (E), and (G), respectively.
All data are presented as mean ± SEM. See also Figures S1 and S2.generated from the MS5-based differentiation protocol
were imaged at day 50 of differentiation and, unlike in
those generated from the floor-plate-based protocol, there666 Stem Cell Reports j Vol. 7 j 664–677 j October 11, 2016were no significant differences in mitochondrial size and
morphology between control and patient lines (Figures
S3A–S3C).
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Figure 2. Abnormal Mitochondria in PD
iPSC-DerivedMidbrainNeuronal Population
(A) Electron microscopy photographs taken
at day 75 of differentiation. Lower panels
are enlarged images of the corresponding
boxed area marked in upper panels. Scale bar,
500 nm.
(B) Percentage of abnormally shaped mito-
chondria among all mitochondria in a given
midbrain neuronal population.
(C) Relative mitochondria size for each line
compared with the average size measured in
H9-derived cells (n = 20–50; mitochondria
from two independent preparations). Signif-
icance levels for individual markers are pre-
sented as comparisons with the H9 wild-type
group: *p < 0.01, ANOVA and Dunnett’s test.
(D) Live staining image of MitoSOX indicating
oxidative mitochondria. Black and white im-
ages in the upper panels and red color in the
lower panels represent MitoSOX labeling, and
blue (lower panels) represents Hoechst for
DNA. Scale bar, 50 mm.
(E) Quantification of relative fluorescence
intensity of MitoSOX by image analysis
(n = 3; independent experiments). Signifi-
cance levels for individual markers are pre-
sented as comparisons with the H9 wild-type
group: *p < 0.001, ANOVA and Dunnett’s test.
All data are presented as mean ± SEM. See
also Figure S3.Mitochondrial Stress and Cell-Type-Specific
Vulnerability in mDA Neurons
To explore functional changes associated with the gross
phenotypic abnormalities in the mitochondria, we
measured mitochondrial-derived oxidants with the
MitoSOX assay (Figures 2D and 2E) as a readout of
mitochondrial stress. PD iPSC-derived mDA cells dis-
played MitoSOX-positive mitochondria widely distributed
throughout the cytosol (Figure 2D). In contrast, the relative
MitoSOX intensity in control iPSC andwild-type ESCmDA
populations was much lower than that of patient neurons
(Figure 2E) and mainly confined to apoptotic, shrunken
cells (Figure 2D). The apparent mitochondrial phenotype
in our PD iPSC-derived mDA neurons and the nature of
the primary genetic defect suggest that mitochondrialdysfunction is likely a driving factor responsible for a vari-
ety of downstream phenotypes.
Next, we investigated whether PINK1 or Parkin iPSC-
derived cells were prone to cell death, since progressive
degeneration of DA neurons in the SN is a prominent
feature of PD. Under standard culture conditions we did
not observe a noticeable difference inmDAneuron survival
between PD and control lines (Figure 3A, upper panels). To
determine whether PD lines are sensitive to mitochondrial
stress, we used CCCP (carbonyl cyanide m-chlorophenyl
hydrazone), a chemical inhibitor of oxidative phosphory-
lation and potential mitochondrial stress inducer, to
explore differences in cell survival (Figure 3A, lower
panels). Cells at days 60–70 of differentiation were treated
with increasing concentrations of CCCP for 48 or 72 hr,Stem Cell Reports j Vol. 7 j 664–677 j October 11, 2016 667
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Figure 3. Vulnerability to Mitochondria
Toxin
(A and D) Immunocytochemical analysis at
day 60 in mDA neurons derived via the floor-
plate-based protocol (A) or MS5 feeder-
based protocol (D) for TUJ1 and TH: treat-
ment with 100 mM CCCP. Scale bars, 50 mm.
(B, C, E, and F) Cell-viability assay with ATP
activity after 48 or 72 hr of CCCP treatment
(day 60 of differentiation of floor-plate-
based protocol [B and C] and MS5 feeder-
based protocol [E and F], three technical
replicates).
All data are presented as mean ± SEM.and cell survival was analyzed using an ATP activity assay.
The results revealed that differentiated mDA cells from
either of the two PD iPSC lines were more vulnerable
than those derived from control iPSC or ESC lines (Figures
3B and 3C). Our data support previous studies (Nguyen
et al., 2011; Shaltouki et al., 2015) suggesting that PD
iPSC-derived mDA neurons are more susceptible to cell
stress and death. This is compatible with clinical observa-
tions noting elevated vulnerability of PD patient DA neu-
rons to cell death due to stressors such as oxidative damage,668 Stem Cell Reports j Vol. 7 j 664–677 j October 11, 2016nitrosative damage, and environmental toxins (Hauser and
Hastings, 2013). Of note, DA populations derived from the
MS5 feeder-based protocol did not exhibit any differences
in vulnerability to CCCP between PD iPSCs and control
lines (Figures 3D–3F).
a-Synuclein Accumulation in PD iPSC-Derived mDA
Neurons
a-Synuclein is a natively unfolded, presynaptic neuronal
protein strongly implicated in PD and Alzheimer’s disease,
and other neurodegenerative disorders (Arima et al., 1998).
Mutations in the SNCA gene or abnormalities in a-synu-
clein expression and regulation (Abeliovich et al., 2000;
Bellucci et al., 2012) are thought to be actively involved
in mDA neuron degeneration and PD pathogenesis. In
particular, aggregation of a-synuclein protein is a key
feature of Lewy bodies, neuronal inclusions that are a path-
ological hallmark of PD. Although the role of a-synuclein
has yet to be fully elucidated, evidence indicates it plays
an important role in the regulation of various neuron-
related mechanisms such as vesicle transport and synaptic
vesicle fusion (Abeliovich et al., 2000; Bendor et al., 2013).
In the context of PD, studies suggest that abnormal aggre-
gation of a-synuclein can be induced by oxidative stress
(Norris et al., 2007; Paxinou et al., 2001; Sherer et al.,
2002), and the presence of oxidized/nitrated a-synuclein
has also been documented in the PD brain (Giasson
et al., 2000). Therefore, we assessed whether a-synuclein
pathology can be observed in vitro in PD iPSC-derived
DA neurons. Quantitative immunocytochemistry and RT-
PCR analyses revealed a progressive increase in a-synuclein
expression during mDA neuron differentiation and
maturation (Figures 4A–4H). However, at the level of gene
expression, we did not observe obvious differences be-
tween control- and PD iPSC-derived cells (Figure 4E).
Expression of a-synuclein by immunocytochemistry was
detected starting at day 45 of differentiation in mDA neu-
rons derived from PD iPSC lines (Figures 4A–4C and 4F).
By day 60, a-synuclein was abundantly expressed across
all groups, but higher in PD than in control iPSC lines. In
addition, PD iPSC-derived neurons showed increased cyto-
plasmic localization of a-synuclein, which was present in a
higher proportion of TH+ neurons compared with control
iPSC- or ESC-derived mDA neurons (Figures 4C and 4G).
In MS5-derived (non-floor-plate) cultures, the percentage
of TH+ cells expressing a-synuclein was lower than in
floor-plate-derived cultures, and no differences were
observed between PD iPSC and control-derived cells (Fig-
ures 4D and 4H). Using the floor-plate protocol, differences
in a-synuclein levels between PD iPSC and control groups
were further corroborated by western blotting analysis
showing elevations in Triton-soluble extracts of PD iPSC
neurons (Figures 5A and 5C). Measurement of neuronal
markers including bIII-tubulin and MAP2 indicated that
control and patient lines differentiated into neurons simi-
larly, suggesting that a-synuclein accumulation occurred
as a pathological process rather than representing a matu-
ration-related difference (Figure 5B). To further address
this issue, we analyzed the levels of tau expression, another
maturation-related marker and a protein prone to aggrega-
tion. Western blotting for tau revealed no change in levels
between control and patient lines, indicating a comparable
maturation state, confirming the specificity of a-synucleinaccumulation in the PINK1 and Parkin patient lines (Fig-
ure 5B). We next measured the specific accumulation of
pathological a-synuclein in patient lines by analyzing
Triton-insoluble extracts by western blot using the a-synu-
clein antibody LB509, which was generated against Lewy
body inclusions (Baba et al., 1998). Elevated levels of insol-
uble a-synuclein were detected in patient lines with LB509,
and confirmed with another a-synuclein antibody, C20
(Figure 5C). Similar biochemical analysis of pathogenic
a-synuclein was performed in MS5-derived neurons,
but no changes between disease and control lines were
observed (Figures S4A–S4D). Immunocytochemical anal-
ysis revealed that a-synuclein-positive cells co-expressed
ubiquitin (Figure S5A), another protein found in Lewy
bodies (Engelender, 2008); however, we did not observe sig-
nificant differences in the levels of total ubiquitin between
disease and control lines (Figure S5B), whichmay be due to
the fact that ubiquitin expression can be regulated inde-
pendently of a-synuclein levels. To determine whether
increased a-synuclein levels in PD iPSC lines resulted
from mutant PINK1, we overexpressed wild-type PINK1
gene via lentiviral transduction at day 35 of differentiation.
At day 53, cells transduced with the PINK1 rescue vector
showed a partial reduction in a-synuclein expression
compared with non-transduced cells and cells transduced
with a control vector (Figures S6A and S6B). These data sug-
gest a possible direct link between a-synuclein accumula-
tion and the underlying genetic abnormality. We further
tried to rescue a-synuclein accumulation by pharmacolog-
ical means using superoxide dismutase (SOD) mimetics
(MnTBAT and EUK134 [10–100 mM]) and N-acetyl-L-
cysteine (1–10 mM), a powerful antioxidant (differentia-
tion day 40–60); however, these pharmacological interven-
tions did not yield significant differences in a-synuclein
levels (data not shown).
Upregulation of Cytosolic Dopamine and Synapsin
Levels
Our data demonstrate a correlation betweenmitochondrial
dysfunction, elevated a-synuclein levels, and greater
vulnerability to CCCP. We hypothesized that increased
a-synuclein levels may also be associated with elevated
cytosolic DA, as previous studies suggest that a-synuclein
regulates DA transmission in DA neurons (Bendor et al.,
2013; Mosharov et al., 2009). To address this question, we
compared the levels of DA in mDA neurons derived from
PD iPSC and control lines. Using high-performance liquid
chromatography (HPLC) analysis with electrochemical
detection, we observed elevated levels of intracellular DA
in Parkin iPSC-derived mDA neurons (Figure 5D). Higher
DA levels may point to hyperactive neurotransmitter
biosynthesis, an increased number of storage or synaptic
vesicles, or decreased DA metabolism. Intracellular DAStem Cell Reports j Vol. 7 j 664–677 j October 11, 2016 669
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Figure 4. Difference in a-Synuclein Accumulation between PD iPSC and Control Lines
(A–D) Immunocytochemical analysis at days 30, 45, and 60 of differentiation for a-synuclein and TH expression from Parkin and PINK1
iPSC lines, control iPSC, and normal ESC (H9) lines. Panels in (A–C) show cells differentiated via the floor-plate-based protocol while panels
in (D) were differentiated via the MS5 feeder-based protocol. Scale bars, 50 mm.
(E) RNA expression of SCNA (a-synuclein) at differentiation days 0, 30, 45, and 60 of each line (n = 9; technical replicates from three
independent experiments).
(F) Quantification of the a-synuclein expression levels presented in (A–C) (n = 3; independent experiments).
(G and H) Quantitative co-expression analysis of a-synuclein and TH at day 60 of differentiation for the floor-plate-based protocol (C) and
MS5 feeder-based protocol (D) (n = 3; independent experiments). Significance levels for individual markers are presented as comparisons
with the H9 wild-type group: *p < 0.001, ANOVA and Dunnett’s test.
All data are presented as mean ± SEM. See also Figures S5 and S6.levels in neurons derived from MS5-based differentiations
were also measured, but there were no significant differ-
ences between control and patient lines (Figure S4E).While
further studies are required to address this question, we670 Stem Cell Reports j Vol. 7 j 664–677 j October 11, 2016observedpreliminary evidenceof increased synapsin inPar-
kin iPSC-derivedDAneurons (Figure5A). This is compatible
with a recent study that demonstrated interaction between
synapsin III and a-synuclein in mice (Zaltieri et al., 2015).
Figure 5. Accumulation of a-Synuclein and DA from PD iPSC-Derived mDA Population
(A) a-Synuclein and synapsin western blot analysis of Triton-soluble extracts from day-55 or day-60 mDA cultures. bIII-Tubulin and GAPDH
were used as loading controls. For all blots, molecular weight is shown in kDa. Right: a-synuclein, bIII-tubulin, and synapsin were
quantified and normalized to GAPDH. Data are expressed as fold change compared with the H9 line (n = 3; independent experiments). C,
control iPSC line. Significance levels for individual markers are presented as comparisons with the H9 wild-type group or the control iPSC
group: *p < 0.05, ANOVA and Tukey’s multiple comparison test.
(legend continued on next page)
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DISCUSSION
Our study reports several PD-associated phenotypes in
mDA neurons derived from Parkin and PINK1 iPSCs. We
focused on these two genetic forms of PD, which have
been implicated in a variety of cellular functions including
vesicular trafficking andmitochondrialmaintenance (Pick-
rell and Youle, 2008). The fact that several disease-related
phenotypes such as mitochondrial morphology, as well as
levels of a-synuclein and cytosolic DA, were observed
only in mDA neurons derived via the floor-plate protocol
(Kriks et al., 2011) but not in cultures differentiated via a
neuroepithelial intermediate on MS5 feeder cells suggests
that the differentiation paradigm can greatly affect the
outcome in PD iPSC-based in vitromodeling studies. Other
recent PD iPSC-based disease modeling studies have
utilized differentiation protocols with TH+ neuron yields
ranging from 10% to 15% (Nguyen et al., 2011; Shaltouki
et al., 2015) and subtype characterization of those TH+ cells
often remains incomplete. The current study was focused
on definingmultiple PD-related disease phenotypes within
a limited set of well-characterized iPSC lines and on deter-
mining the impact of distinct differentiation protocols
within a given disease line. However, it will be important
to confirm our results across a larger set of PD iPSC lines
in the future.
It is noteworthy that while a-synuclein (SNCA) gene
expression was unchanged across cell lines, immunostain-
ing provided evidence of a-synuclein accumulation local-
ized to the cytosol in the PD iPSC lines. It is well known
that a-synuclein can exist in several different forms (Mar-
ques and Outeiro, 2012). Studies point toward the oligo-
meric and fibrillary a-synuclein species as being the toxic
and pathogenic forms present in Parkinson’s disease while
the monomeric or tetrameric a-synuclein are likely physio-
logical forms (Bartels et al., 2011; Marques and Outeiro,
2012). Future research should address whether in addition
to increased protein levels and changes in a-synuclein cyto-
plasmic localization, PD iPSC-derived mDA neurons also
exhibit changes in the ratio of oligomeric and fibrillary spe-(B) Western blot analysis for MAP2C and tau. Coomassie brilliant blue (
shown in kDa. Right: quantification of tau and MAP2c indicate similar
experiments). The dashed line indicates cropped-out replicates, but
(C) Western blot analysis of Triton-insoluble a-synuclein using antibo
Lower panels: quantification of insoluble a-synuclein, normalized to b
individual markers are presented as comparisons with the H9 wild-ty
multiple comparison test.
(D) HPLC analysis for intracellular DA level at differentiation day 90 f
(H9) line (n = 6; independent experiments). Significance levels for DA
comparisons with those measured in control mDA neurons (H9 and w
test: **p < 0.01; n.s., not significant.
All data are presented as mean ± SEM. See also Figure S4.
672 Stem Cell Reports j Vol. 7 j 664–677 j October 11, 2016cies. Interestingly, our results on the expression of a-synu-
clein in Parkin iPSC-derivedmDAneurons are distinct from
those of a previous study (Jiang et al., 2012), which re-
ported no differences between disease and wild-type lines,
but coincident with findings of partially upregulated a-syn-
uclein in a subset of Parkin patient PD lines (Imaizumi
et al., 2012). Evidence of a-synuclein accumulation is
particularly intriguing for PARK2/Parkin mutant cells as
many patients, particularly those carrying heterozygous
mutations (Farrer et al., 2001), lack Lewy bodies at autopsy.
In the study by Imaizumi et al. (2012), a-synuclein accumu-
lation was observed in iPSC-derived DA neurons from a ho-
mozygous patient with a deletion in exons 2–3 but not in
cells from another homozygous Parkin patient with dele-
tions in exons 6 and 7. These results correlated with the
presence or absence of Lewy bodies in autopsy data from
the matched patient or family member. The Parkin iPSC
line in our study was derived from a patient with a homo-
zygous deletion in exon 9 with unknown patient pathol-
ogy. A factor that may explain the presence or absence of
a-synuclein accumulation in iPSC-derived DA neuron cul-
tures is the specific differentiation protocol used. This is
illustrated in our study by the absence of a-synuclein accu-
mulation in MS5-derived cultures. Additional studies are
required to further explore the mechanisms involved in
the differences in a-synuclein levels across DA neuron pro-
tocols and PARK2/Parkin genotypes.
In addition, we observed significantly elevated levels of
synapsin and dopamine in Parkin cultures, although the
changes in PINK1 cells did not reach statistical significance
when compared with control iPSC- or ESC-derived floor-
plate mDA neurons. Increased DA levels may appear, in
contrast to the well-known loss of DA in the brain of PD pa-
tients. While reduction in the PD brain may simply reflect
the progressive loss of DA-producing neurons, there are
data suggesting a reduction in DA levels or release in the re-
maining cells (Nguyen et al., 2011). Our HPLC data argue
for an increase in intracellular dopamine levels in PD versus
control iPSC-derived mDA neurons, which may be indica-
tive of dysregulation of neurotransmitter release linked toCBB) was used as a loading control. For all blots, molecular weight is
neuralization between control and patient lines (n = 3; independent
all samples were run on the same gel.
dies LB509 and C20. For all blots, molecular weight is shown in kDa.
III-tubulin (n = 3; independent experiments). Significance levels for
pe group or the control iPSC group: *p < 0.05, ANOVA and Tukey’s
rom Parkin and PINK1 iPSC lines, control iPSC line, and normal ESC
measured in Parkin or PINK1-derived mDA neurons are presented as
ild-type iPSC groups) by ANOVA and Dunnett’s multiple comparison
Figure 6. Proposed Model of the Pathogenic Loop in Parkin-
and PINK1-Derived mDA Neurons
Mutations in PARK2/Parkin and PINK1 at the origin of the disease
phenotype trigger changes in mitochondrial homeostasis,
which initiate multiple pathogenic changes throughout the cell.
Dysregulation in various cellular functions ultimately induces cell-
type-specific toxic cues, degeneration, and cell death in mDA
neurons. ROS, reactive oxygen species.changes in synaptic activity. In support of our findings, pre-
vious animal studies have also reported increased levels of
DA and DOPAC in Parkin- and PINK1-deficient mice (Ki-
tada et al., 1998). Alternatively, this could be due to a lossof ATP and the proton gradient, which determines the syn-
aptic vesicle-to-cytosol equilibrium of DA. It will be impor-
tant to address whether such changes are limited to the Par-
kin, or potentially, the PINK1 phenotype or reflect changes
in other genetic or sporadic forms of PD at distinct stages
of disease. It is tempting to speculate whether increased
levels could contribute to the pathogenic cycle induced
by mitochondrial dysfunction and ultimately lead to
mDA neuronal cell death (Figure 6).
Determining the role of a-synuclein in PD pathogenesis
is complicated by the fact that the physiological role of
a-synuclein is not fully known; nevertheless, studies
have linked a-synuclein to a variety of functions including
the regulation of synaptic membrane processes and regula-
tion of neurotransmitter release (Davidson et al., 1998;
Nemani et al., 2010). Notably, a-synuclein has also been
found to act as a negative regulator of synaptic vesicle
fusion and exocytotic DA release, and studies have found
that its overexpression impairs DA transmission in the
early phases of neurodegeneration (Gaugler et al., 2012;
Platt et al., 2012). Along these lines, other groups have
found that absent or mutated a-synuclein can affect the
compartmentalization of presynaptic DA and alter DA
storage-pool capacity (Abeliovich et al., 2000; Mosharov
et al., 2006; Murphy et al., 2000; Yavich et al., 2004).
Furthermore, phage display and nuclear magnetic reso-
nance spectroscopy have revealed that synapsin Ia is a
binding partner of a-synuclein, which suggests that their
interaction may play a critical role in the release of neuro-
transmitters (Woods et al., 2007). These results indicate
that increased intracellular levels of DA observed in PD
iPSC mDA neurons could be related to vesicular trafficking
defects caused by a-synuclein protein dysfunction and
other synaptic changes. Increased reactive oxygen species
(ROS) resulting from defective mitochondria in PD mDA
neurons may trigger destruction of synaptic vesicles,
disrupt proper encapsulation of DA within vesicles, and
cause the loss of the proton gradient required for synaptic
vesicles to accumulate DA against its concentration
gradient. Such abnormal DA homeostasis could eventually
perpetuate a cascade of oxidative stress within already
vulnerable cells.
In conclusion, our study illustrates the utility of the floor-
plate-based mDA neuronal differentiation protocol for
modeling aspects of PD in patient-specific cells. The results
indicate that the identity of iPSC-derived mDA neurons is
a critical factor in defining disease-relevant phenotypes
for in vitro models. Our data further suggest a pathogenic
loop involving mitochondrial dysfunction, elevated
a-synuclein, synaptic dysfunction, DA accumulation, and
increased oxidative stress and ROS. Studies will be required
in the future to test this model using alternative strategies
and to define whether similar mechanisms are involvedStem Cell Reports j Vol. 7 j 664–677 j October 11, 2016 673
in other genetic or sporadic forms of PD and relevant
neurodegenerative disorders.EXPERIMENTAL PROCEDURES
Culture of Undifferentiated ESCs and iPSCs Including
PD Patient iPSCs
PD iPSCs generated by retroviral overexpression of OCT4, SOX2,
KLF4, and C-MYC from patients with mutations in PARK2/Parkin
(B125 line) or PINK1 (L2122 line) were generously provided by
theD. Krainc laboratory (NorthwesternUniversity Feinberg School
of Medicine). Information about patients and familial control is
provided in Table S1. ESC lines H9 (WA-09, passages 35–45) and
iPSC lines B125 (passages 20–30; PARK2/Parkin mutated line),
L2122 (passages 20–30; PINK1 mutated line), and L2131 and
L2135 (passages 20–30; familial controls of PINK1mutated patient)
weremaintained onmouse embryonic fibroblasts (Global Stem) in
20%knockout serum replacement (Invitrogen)-containing human
ESC medium as described previously (Kim et al., 2011). This study
had been reviewed by the Tri-SCI ESCRO Committee (protocol
number 2010-09-001).
Neuronal Differentiation
For FP-based mDA neuron induction, a modified version of the
dual-SMAD inhibition was used based on our previously described
differentiation protocol (Kriks et al., 2011). For rosette-based DA
neuron induction we followed our previously described protocols
(Perrier et al., 2004) but used dual-SMAD inhibition to accelerate
the initial neural induction step. See Supplemental Experimental
Procedures for details of the protocol.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde and blocked with 1%
BSA with 0.3% Triton X-100. Primary antibodies were diluted in
1%–5%BSA and incubated according to themanufacturer’s recom-
mendations. A comprehensive list of antibodies and sources is
provided in Table S2. Appropriate Alexa Fluor 488-, 555-, or 647-
conjugated secondary antibodies (Molecular Probes) were used
with DAPI nuclear counterstain (Thermo Fisher).
Electrophysiology
Whole-cell current-clamp recordings were performed. See Supple-
mental Experimental Procedures for detailed recording conditions.
Electron Microscopy
All steps were conducted as previously described (Milner et al.,
2011). See Supplemental Experimental Procedures for procedural
details. Cell morphology and organelles were identified using stan-
dard criteria (Peters et al., 1991). We assessed 20–50 mitochondria
(n) in each group randomly selected from 10–20 images (approxi-
mately 250 mm2 from Parkin iPSC, 600 mm2 from PINK1 iPSC,
450 mm2 from control iPSC, and 500 mm2 from H9 ESC). Samples
were prepared from two independent preparations. Abnormal
mitochondria were identified based on enlarged length (elon-
gated) or size (swollen). To be counted as abnormal in length
or size, mitochondria needed to show a change of >1.5-fold674 Stem Cell Reports j Vol. 7 j 664–677 j October 11, 2016above the respective average values in matched H9 ESC-derived
cultures.
Mitochondrial ROS Assessment
Cells were stained with MitoSOX Red mitochondrial superoxide
indicator (Life Technologies) at a final concentration of 20 mM in
cell-culture medium. Staining was carried out in a 37C incubator
for 30 min. Hoechst dye was used for counterstaining. Quantifica-
tion of the fluorescence intensity that oxidized the MitoSOX
reagent was performed with ImageJ (NIH) and averaged for three
independent experiments.
Cell-Viability Assay
To measure cell vulnerability against stress, we administered 1.56,
3.12, 6.25, 12.5, 25, 50, and 100 mMCCCP (Sigma) to differentiated
cell populations of days 60–70 from each line. After 48 or 72 hr of
treatment, cell survival was measured with CellTiter-Glo Lumines-
cent Cell Viability Assay (Promega) with three technical replicates.
Luminescent activity was acquired on the EnSpire plate reader
(PerkinElmer).
qPCR
Total RNA at days 0, 30, 45, and 60 of each of the line were reverse
transcribed (Quantitech, Qiagen) and amplified material was de-
tected using commercially available Taqman gene-expression
assays (Applied Biosystems) with the data normalized to hypo-
xanthine phosphoribosyltransferase 1 (HPRT). Each data point
represents nine technical replicates from three independent
experiments.
Western Blotting
Neuronal cultures were scraped and proteins from cell pellets were
extracted using 1% Triton X-100 extraction buffer as previously
described (Mazzulli et al., 2011). Antibodies used for western blot-
ting were anti-a-synuclein (Syn211, 1:1,000, Sigma; LB509, 1:500,
Abcam; C20, 1:2,000, Santa Cruz Biotechnology), anti-bIII-tubulin
(1:6,000, Sigma), and anti-glyceraldehyde 3-phosphate dehydro-
genase (GAPDH, 1:5,000, Millipore). Detection was done using
fluorescently labeled secondaries (Alexa 680 or IRDye 800),
scanned and analyzed using the Odyssey infrared imaging system
(LI-COR Biosciences). Integrated band intensities of a-synuclein or
normalizing controls were quantified from three different culture
sets. ANOVA with Tukey’s post hoc test was used for statistical
analysis (GraphPad Prism software).
DA Measurements
To measure the intracellular DA level, we manually lysed 65-day-
old mDA neurons in PBS containing 1% Triton X-100 and
200 mM ascorbic acid (Sigma). After a 15-min spin, the superna-
tant was collected. From each sample, an aliquot was removed
directly to measure protein concentration. The remaining
amount was loaded for DA measurement by HPLC with electro-
chemical detection as previously described (Studer et al., 1996) or
the Dopamine Research ELISA kit (LDN). Cells in each sample
were collected to normalize for protein content. DA concentra-
tions in each group of samples were normalized to the levels
in the corresponding control group; data are shown as averaged
normalized values from six independent experiments (floor
plate) and four technical replications from two independent ex-
periments (MS5).Lentiviral Induction
Human PINK1-V5 cDNA were cloned into lentiviral pER4 vectors
containing a neuron-specific PGK promoter (De´glon et al., 2000).
Virus production was conducted according to standard protocols.
Cells were infected on day 35 of differentiation with an MOI of
1–5. Infection efficiencies of PINK1-V5 virus (80%) were analyzed
by immunostaining at 25 days post infection.Quantification
The percentages of marker-positive cells at the FP (day 11), mDA
neuron precursor (day 25), andmature DA neuron (day 50 or later)
stages were determined in samples derived from at least three inde-
pendent experiments. Images for quantification were selected in a
uniform random manner and each image was scored first for the
number of DAPI-positive nuclei, followed by counting the number
of cells expressing themarker of interest. ImageJ was used for some
cases of image quantification. All data are presented as mean ±
SEM. Statistical analysis was performed using Student’s t test
(comparing two groups) or ANOVAwithDunnett’s test (comparing
multiple groups against control).
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